Phase 1 study to evaluate safety and preliminary efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in patients with locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (PDAC)

被引：0
|
作者：
Abi-Jaoudeh, Nadine
Valerin, Jennifer Brooke
Imagawa, David K.
Preise, Dina
Sacks, Zachary
Cohen, Yaniv
Rothman, Julia
Brook, Keren
Morag, Eyal
Scherz, Avigdor Joshua
Krasnopolskaya, Inna
Alpert, Genia
Chung, Vincent
Melstrom, Laleh Golkar
Kessler, Jonathan
机构：
[1] Univ Calif Irvine, Div Vasc & Intervent Radiol, Dept Radiol Sci, Orange, CA USA
[2] Univ Calif Irvine, Irvine, CA USA
[3] Univ Calif Irvine, Irvine, CA USA
[4] Impact Biotech, Ness Ziona, Israel
[5] Steba Impact Biotech, Ness Ziona, Israel
[6] Weizmann Inst Sci, Dept Plants & Environm Sci, Rehovot, Israel
[7] City Hope Natl Med Ctr, Duarte, CA USA
[8] City Hope Natl Med Ctr, Med Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4204
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma
    Cui, Jiujie
    Yang, Haiyan
    Liu, Jue
    Chen, Donghui
    Hu, Jiong
    Zhang, Haiyan
    Wang, Yu
    Han, Ting
    Mao, Tiebo
    Jiao, Feng
    Biskup, Ewelina
    Pan, Yaotian
    Liu, Min
    Wang, Liwei
    BMC CANCER, 2021, 21 (01)
  • [22] A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma
    Jiujie Cui
    Haiyan Yang
    Jue Liu
    Donghui Chen
    Jiong Hu
    Haiyan Zhang
    Yu Wang
    Ting Han
    Tiebo Mao
    Feng Jiao
    Ewelina Biskup
    Yaotian Pan
    Min Liu
    Liwei Wang
    BMC Cancer, 21
  • [23] A phase II multi-institutional study to evaluate gemcitabine and fractionated stereotactic body radiotherapy for unresectable, locally advanced pancreatic adenocarcinoma
    Herman, Joseph M.
    Chang, Daniel Tandel
    Goodman, Karyn A.
    Wild, Aaron Tyler
    Laheru, Dan
    Zheng, Lei
    Diaz, Luis A.
    Dung Thi Le
    Raman, Siva P.
    Leal, Jeffrey P.
    Chaudhry, Muhammad Ali
    Sugar, Elizabeth
    Columbo, Laurie Ann
    Tom, Ashlyn
    Limaye, Maneesha R.
    Edil, Barish H.
    Oteiza, Katharine
    Hacker-Prietz, Amy
    Wolfgang, Christopher Lee
    Koong, Albert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Randomized phase II study of WT1 peptide vaccine plus gemcitabine for advanced pancreatic ductal adenocarcinoma (PDAC): Clinical efficacy and immune response
    Nishida, Sumiyuki
    Ishikawa, Takeshi
    Kokura, Satoshi
    Egawa, Shinichi
    Koido, Shigeo
    Yasuda, Hiroaki
    Yanagimoto, Hiroaki
    Ishii, Jun
    Kanno, Yoshihide
    Oba, Mari Saito
    Sato, Maho
    Morimoto, Soyoko
    Eguchi, Hidetoshi
    Nagano, Hiroaki
    Homma, Sadamu
    Oka, Yoshihiro
    Morita, Satoshi
    Sugiyama, Haruo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
    Jeong, J. H.
    Yoo, C.
    Kim, K-P.
    Chang, H-M.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 263 - 263
  • [26] MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).
    Cassier, Philippe Alexandre
    Garin, Gwenaelle
    Eberst, Lauriane
    Delord, Jean-Pierre
    Chabaud, Sylvie
    Terret, Catherine
    Montane, Laure
    Bidaux, Anne-Sophie
    Laurent, Severine
    Jaubert, Lise
    Ferlay, Celine
    Bernardin, Mathilde
    Tabone-Eglinger, Severine
    Gilles-Afchain, Laurence
    Menetrier-Caux, Christine
    Caux, Christophe
    Treilleux, Isabelle
    Perol, David
    Gomez-Roca, Carlos Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Phase I/ II Study of Concurrent Chemoradiotherapy With Gemcitabine and S-1 for Unresectable Locally Advanced Pancreatic Adenocarcinoma
    Ioka, T.
    Arimoto, N.
    Ashida, R.
    Takakura, R.
    Nakamura, S.
    Nishiyama, K.
    Tanaka, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S451 - S451
  • [28] Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma
    Lee, Jae-Lyun
    Kim, Song Cheol
    Kim, Ji-Hoon
    Lee, Sang Soo
    Kim, Tae-Won
    Park, Do Hyun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Kim, Jong Hoon
    Park, Jin-Hong
    Shin, Sang Hyun
    Han, Duck Jong
    SURGERY, 2012, 152 (05) : 851 - 862
  • [29] A Phase 2 Multicenter Study to Evaluate Gemcitabine and Fractionated Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Adenocarcinoma
    Dholakia, A. S.
    Chang, D. T.
    Goodman, K. A.
    Raman, S. P.
    Hacker-Prietz, A.
    Griffith, M. E.
    Colombo, L.
    Laheru, D. A.
    Koong, A. C.
    Herman, J. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S28 - S28
  • [30] A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).
    Hong, Theodore S.
    Yeap, Beow Y.
    Horick, Nora K.
    Wo, Jennifer Yon-Li
    Weekes, Colin D.
    Allen, Jill N.
    Qadan, Motaz
    Oberstein, Paul Eliezer
    Jain, Rakesh K.
    Blaszkowsky, Lawrence Scott
    Wolpin, Brian M.
    Laheru, Daniel A.
    Messersmith, Wells A.
    Ly, Leilana
    Drapek, Lorraine C.
    Ting, David Tsai
    Burkhart, Richard A.
    Fernandez-del Castillo, Carlos
    Kimmelman, Alec
    Ryan, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 719 - 719
12345